Skip to main content
Top
Published in: Tumor Biology 12/2014

01-12-2014 | Research Article

RETRACTED ARTICLE: The effect of chemokine CC motif ligand 19 on the proliferation and migration of hepatocellular carcinoma

Authors: Ke-qin Luo, Yi-ni Shi, Ji-cai Peng

Published in: Tumor Biology | Issue 12/2014

Login to get access

Abstract

Multiple studies have shown that CC motif chemokine ligand 19 (CCL19) promotes cell proliferation in several human cancers. The aim of this study was to investigate the expression and function of CCL19 in hepatocellular carcinoma (HCC). Quantitative reverse transcription-polymerase chain reaction (qRT-PCR), Western blot, and immunohistochemistry were performed separately to detect the expression of CCL19 in HCC tissues. The expression of CCL19 and its receptor (CCR7) in different HCC cell lines were screened by Western blot. HCC cell lines were screened and processed with recombinant human CCL19 (rhCCL19) or si-CCL19 RNA. Cell proliferation assay and transwell assay were performed to evaluate the proliferation and migration of HCC cells, respectively. Low expression of CCL19 was observed in 83.72 % (72/86) of the HCC versus 16.67 % (4/24) of the adjacent non-tumorous liver tissues, the difference of CCL19 expression between HCC and adjacent non-tumorous liver tissues was statistically significant (P < 0.001). The expression level of CCL19 mRNA and protein in tumor tissues was significantly lower than adjacent non-tumorous liver tissues. The proliferation and migration of HCC cells were obviously inhibited in rhCCL19-treated groups. Our data suggest that CCL19 may play a suppressive role in the regulation of aggressiveness in human HCC.
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2.
go back to reference Ades S. Adjuvant chemotherapy for colon cancer in the elderly: moving from evidence to practice. Oncology (Williston Park). 2009;23:162–7. Ades S. Adjuvant chemotherapy for colon cancer in the elderly: moving from evidence to practice. Oncology (Williston Park). 2009;23:162–7.
3.
go back to reference Frangov T, Gaĭdarski R, Dimitrova V, Popov V, Grozeva K, Rusenov D. Prognostic factors for survival in primary liver cancer. Khirurgiia (Sofiia). 2007;6:36–9. Frangov T, Gaĭdarski R, Dimitrova V, Popov V, Grozeva K, Rusenov D. Prognostic factors for survival in primary liver cancer. Khirurgiia (Sofiia). 2007;6:36–9.
4.
go back to reference El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.CrossRef El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.CrossRef
5.
go back to reference Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer. 2011;11:573–87.CrossRef Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer. 2011;11:573–87.CrossRef
6.
go back to reference Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med. 1998;188:373–86.CrossRef Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med. 1998;188:373–86.CrossRef
7.
go back to reference Hamanishi J, Mandai M, Matsumura N, et al. Activated local immunity by CC chemokine ligand19-transduced embryonic endothelial progenitor cells suppresses metastasis of murine ovarian cancer. Stem Cells. 2010;28:164–73.CrossRef Hamanishi J, Mandai M, Matsumura N, et al. Activated local immunity by CC chemokine ligand19-transduced embryonic endothelial progenitor cells suppresses metastasis of murine ovarian cancer. Stem Cells. 2010;28:164–73.CrossRef
8.
go back to reference Johrer K, Pleyer L, Olivier A, Maizner E, Zelle-Rieser C, Greil R. Tumour-immune cell interaction smodulated by chemokines. Expert Opin Biol Ther. 2008;8:269–90.CrossRef Johrer K, Pleyer L, Olivier A, Maizner E, Zelle-Rieser C, Greil R. Tumour-immune cell interaction smodulated by chemokines. Expert Opin Biol Ther. 2008;8:269–90.CrossRef
9.
go back to reference Wang W, Huang P, Zhang L, Wei J, Xie Q, Sun Q, et al. Antitumor efficacy of C-X-C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo. Cancer Sci. 2013;104:1523–31.CrossRef Wang W, Huang P, Zhang L, Wei J, Xie Q, Sun Q, et al. Antitumor efficacy of C-X-C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo. Cancer Sci. 2013;104:1523–31.CrossRef
10.
go back to reference Gao Q, Zhao YJ, Wang XY, Qiu SJ, Shi YH, Sun J, et al. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Res. 2012;72:3546–56.CrossRef Gao Q, Zhao YJ, Wang XY, Qiu SJ, Shi YH, Sun J, et al. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Res. 2012;72:3546–56.CrossRef
11.
go back to reference Itakura M, Terashima Y, Shingyoji M, et al. High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients. Br J Cancer. 2013;109:1100–8.CrossRef Itakura M, Terashima Y, Shingyoji M, et al. High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients. Br J Cancer. 2013;109:1100–8.CrossRef
12.
go back to reference Cao M, Deng HX, Zhao J, Fan LY, Jiang Y, Wen YJ, et al. Antitumour activity of cationic-liposome-conjugated adenovirus containing the CCL19 [chemokine (C-C motif) ligand 19] gene. Biotechnol Appl Biochem. 2007;48:109–16.CrossRef Cao M, Deng HX, Zhao J, Fan LY, Jiang Y, Wen YJ, et al. Antitumour activity of cationic-liposome-conjugated adenovirus containing the CCL19 [chemokine (C-C motif) ligand 19] gene. Biotechnol Appl Biochem. 2007;48:109–16.CrossRef
13.
go back to reference Lu J, Zhao J, Feng H, Wang P, Zhang Z, Zong Y, et al. Antitumor efficacy of CC motif chemokine ligand 19 in colorectal cancer. Dig Dis Sci. 2014;59(9):2153–62. Lu J, Zhao J, Feng H, Wang P, Zhang Z, Zong Y, et al. Antitumor efficacy of CC motif chemokine ligand 19 in colorectal cancer. Dig Dis Sci. 2014;59(9):2153–62.
14.
go back to reference Oliveira-Neto HH, de Souza PP, da Silva MR, Mendonça EF, Silva TA, Batista AC. The expression of chemokines CCL19, CCL21 and their receptor CCR7 in oral squamous cell carcinoma and its relevance to cervical lymph node metastasis. Tumour Biol. 2013;34:65–70.CrossRef Oliveira-Neto HH, de Souza PP, da Silva MR, Mendonça EF, Silva TA, Batista AC. The expression of chemokines CCL19, CCL21 and their receptor CCR7 in oral squamous cell carcinoma and its relevance to cervical lymph node metastasis. Tumour Biol. 2013;34:65–70.CrossRef
15.
go back to reference Shang ZJ, Liu K, Shao Z. Expression of chemokine receptor CCR7 is associated with cervical lymphnode metastasis of oral squamous cell carcinoma. Oral Oncol. 2009;45:48–55.CrossRef Shang ZJ, Liu K, Shao Z. Expression of chemokine receptor CCR7 is associated with cervical lymphnode metastasis of oral squamous cell carcinoma. Oral Oncol. 2009;45:48–55.CrossRef
16.
go back to reference Kochetkova M, Kumar S, McColl S. R: Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death Differ. 2009;16:664–73.CrossRef Kochetkova M, Kumar S, McColl S. R: Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death Differ. 2009;16:664–73.CrossRef
Metadata
Title
RETRACTED ARTICLE: The effect of chemokine CC motif ligand 19 on the proliferation and migration of hepatocellular carcinoma
Authors
Ke-qin Luo
Yi-ni Shi
Ji-cai Peng
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2578-5

Other articles of this Issue 12/2014

Tumor Biology 12/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine